Literature DB >> 3105452

In vivo synergism of roxithromycin (RU 965) and interferon against Toxoplasma gondii.

J M Hofflin, J S Remington.   

Abstract

We investigated the activity of roxithromycin (RU 965) and gamma interferon alone and in combination in a murine model of toxoplasmic encephalitis. Roxithromycin at a dosage of 35 or 50 mg per mouse per day decreased mortality. Gamma interferon alone significantly prolonged time to death. When combined, the two agents were remarkably synergistic.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3105452      PMCID： PMC174724          DOI： 10.1128/AAC.31.2.346

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Interferon: protection of cells infected with an intracellular protozoan (Toxoplasma gondii).

Authors:  J S Remington; T C Merigan
Journal:  Science       Date:  1968-08-23       Impact factor: 47.728

2.  Effect of murine interferon gamma on murine toxoplasmosis.

Authors:  R E McCabe; B J Luft; J S Remington
Journal:  J Infect Dis       Date:  1984-12       Impact factor: 5.226

3.  Inhibition of growth of Toxoplasma gondii in cultured fibroblasts by human recombinant gamma interferon.

Authors:  E R Pfefferkorn; P M Guyre
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

4.  Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome.

Authors:  F M Gordin; G L Simon; C B Wofsy; J Mills
Journal:  Ann Intern Med       Date:  1984-04       Impact factor: 25.391

5.  Assessment of therapy for pneumocystis carinii pneumonia. PCP Therapy Project Group.

Authors:  H W Haverkos
Journal:  Am J Med       Date:  1984-03       Impact factor: 4.965

6.  In vivo recombinant interleukin 2 administration enhances survival against a lethal challenge with Toxoplasma gondii.

Authors:  S D Sharma; J M Hofflin; J S Remington
Journal:  J Immunol       Date:  1985-12       Impact factor: 5.422

7.  Activation of neonatal and adult human macrophages by alpha, beta, and gamma interferons.

Authors:  C B Wilson; J Westall
Journal:  Infect Immun       Date:  1985-08       Impact factor: 3.441

8.  Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity.

Authors:  C F Nathan; H W Murray; M E Wiebe; B Y Rubin
Journal:  J Exp Med       Date:  1983-09-01       Impact factor: 14.307
  8 in total
  11 in total

Review 1.  New directions for macrolide antibiotics: structural modifications and in vitro activity.

Authors:  H A Kirst; G D Sides
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

Review 2.  Animal models in interferon research: some current trends.

Authors:  H Schellekens
Journal:  Experientia       Date:  1989-06-15

3.  Activity of gamma interferon in combination with pyrimethamine or clindamycin in treatment of murine toxoplasmosis.

Authors:  D Israelski; J Remington
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-05       Impact factor: 3.267

4.  Effect of clindamycin on pneumonia from reactivation of Toxoplasma gondii infection in mice.

Authors:  G A Filice; C Pomeroy
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

5.  In vivo activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin against Toxoplasma gondii.

Authors:  F G Araujo; R M Shepard; J S Remington
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-06       Impact factor: 3.267

6.  Comparative activity of macrolides against Toxoplasma gondii demonstrating utility of an in vitro microassay.

Authors:  S Chamberland; H A Kirst; W L Current
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

Review 7.  Role of gamma interferon in Toxoplasma gondii infection.

Authors:  C S Subauste; J S Remington
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-02       Impact factor: 3.267

Review 8.  Current recommendations and future prospects in the treatment of toxoplasmosis.

Authors:  R E McCabe; S Oster
Journal:  Drugs       Date:  1989-12       Impact factor: 9.546

9.  In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii.

Authors:  H R Chang; J C Pechère
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

10.  Synergistic combination of azithromycin and sulfadiazine for treatment of toxoplasmosis in mice.

Authors:  F G Araujo; T Lin; J S Remington
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-01       Impact factor: 3.267
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.